What Is Actually in That Peptide Vial? Often, Nobody Can Tell You.
The compounded GLP-1 boom is ending, and the research-peptide market is next. The real issue is not just legality. For these products, no one can reliably tell you what is in the vial.
Peptides in Women’s Health · Part 6 of 7
The least-proven end of the spectrum: the compounded and research-peptide market, and why the absence of a rule is not evidence of safety.
In 2025 the legal pathway that built the compounded GLP-1 industry began to close, and in April 2026 the FDA moved to shut it permanently.
The wider research-peptide market is next.
The reason is not only legal.
For these products, no one can reliably tell you what is in the vial.
Peptides sold outside the approved-drug system come through two side doors. One is compounding, where pharmacies mix a version of a drug. During the GLP-1 shortages, compounded semaglutide and tirzepatide were widely available. The other is the research peptide market, where products like BPC-157 are sold labeled for research use only while being marketed for people. Both bypass the testing that approved drugs go through for safety, purity, and dose.
When a product skips that testing, the patient inherits the uncertainty. Unknown purity.
Unknown dose.
Unknown contaminants.
For a healthy adult that is a gamble.
For a woman who is pregnant, trying to conceive, or breastfeeding, it is a gamble with a second person’s development on the table.
Paid subscribers continue below.
